Biomarkers in Cancer Detection and Monitoring of Therapeutics
Volume 1: Discovery and Technologies
- 1st Edition - November 16, 2023
- Imprint: Academic Press
- Editors: Ranbir Chander Sobti, Awtar Krishan, Aastha Sobti
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 1 1 6 - 6
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 1 1 7 - 3
Biomarkers in Cancer Detection and Monitoring of Therapeutics, Volume One, Discovery and Technologies discusses how molecular biomarkers are used to determine predis… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteBiomarkers in Cancer Detection and Monitoring of Therapeutics, Volume One, Discovery and Technologies discusses how molecular biomarkers are used to determine predisposition, facilitate detection, improve treatment and offer prevention guidelines for different cancer types. This first volume in the series focuses on techniques and approaches recently developed to assist in the decision of which biomarker to use for specific conditions. Topics covered include circulating tumor cells and circulating tumor DNA, exomes, tumor microenvironment, gene editing, artificial intelligence and robotics. In addition, the book discusses the development and applications of organoids and precision medicine.This book will be a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of biomarkers in cancer research.
- Provides up-to-date information on current molecular biomarkers research for cancer
- Presents basic research aspects and novel technologies applied in the discovery of new biomarkers
- Discusses several technologies, including artificial intelligence, robotics, data mining, gene editing, omics and their applicability for specific cancer types
Researchers and graduate students on cancer research, oncologists, Clinical researchers
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One Milestones in cancer research
- Abstract
- 1 Introduction
- 2 Landmark researches
- 3 Summary
- References
- Chapter Two Cancer burden: Epidemiology, racial, and geographical disparities
- Abstract
- 1 Introduction
- 2 Global burden of cancer
- 3 Social class disparities in cancer
- 4 Racial disparities in cancer
- 5 Risk factors for cancer
- 6 Reasons for disparities in cancer
- 7 Response to the burden of cancer
- 8 Conclusion
- References
- Chapter Three Technological evolution in cancer diagnosis and therapeutics
- Abstract
- 1 Introduction
- 2 Cancer diagnosis
- 3 Cancer therapy
- 4 Conclusion
- References
- Chapter Four How does time speak about cancer, its diagnosis, treatments, and challenges?
- Abstract
- Acknowledgment
- 1 Introduction
- 2 What causes cancer?
- 3 New knowledge about cause of cancer
- 4 Animal models and chemical carcinogenesis
- 5 History of cancer treatment
- 6 Major breakthroughs in cancer research
- 7 Cancer in India since antiquity
- 8 Conclusion
- References
- Chapter Five Role of artificial intelligence in cancer diagnostics and therapeutics
- Abstract
- 1 Introduction
- 2 Artificial intelligence in cancer diagnostics
- 3 Artificial intelligence in cancer drug therapy
- 4 Limitations to artificial intelligence in cancer diagnostics and therapeutics
- 5 Future prospective of artificial intelligence in cancer management
- References
- Chapter Six Addressing the diagnosis and therapeutics of malignant tumor cells
- Abstract
- Acknowledgment
- 1 Introduction
- 2 Tumor-related factors; tumor stage at diagnosis
- 3 Tumor subtype and location
- 4 Prior consultations and usage of health-care services
- 5 Preceding symptomatic presentations
- 6 Health-care factors
- 7 Patient factors
- 8 Age of the patient
- 9 Breast cancer
- 10 Lung cancer
- 11 Prostate cancer
- 12 Ovarian cancer
- 13 Other cancers
- 14 Biomarkers; imaging technique
- 15 Nanomedicine
- 16 Extracellular vesicles (EV) for cancer diagnosis and therapy
- 17 Natural antioxidants in cancer therapy
- 18 Targeted therapy and immunotherapy
- 19 Gene therapy for cancer treatment
- 20 Conclusion
- References
- Chapter Seven Insights into genetic predisposition of somatic cancers
- Abstract
- 1 Introduction
- 2 Germline cancers
- 3 Somatic cancers
- 4 Identifying somatic mutations
- 5 Next-generation sequencing (NGS) in mutation detection
- References
- Chapter Eight The use of tumor markers in prognosis of cancer and strategies to prevent cancer predisposition and progress
- Abstract
- 1 Introduction
- 2 The use of tumor markers in prognosis of cancer
- 3 Strategies to prevent cancer predisposition and progress
- 4 Conclusions and recommendations
- References
- Further reading
- Chapter Nine Cytogenetics to multiomics in biology of cancer
- Abstract
- 1 Introduction
- 2 Karyotyping
- 3 Recent advances
- 4 Conclusion
- References
- Chapter Ten Role of noncoding RNA as biomarkers for cancer
- Abstract
- 1 Introduction
- 2 Micro RNA
- 3 Amplification or deletion of miRNA genes
- 4 Dysregulated epigenetic changes
- 5 Defects in miRNA biogenesis machinery
- 6 Long noncoding RNAs
- 7 Regulatory functions of housekeeping ncRNAs
- 8 LncRNA modes of action in the nucleus
- 9 Characteristics and functions of long noncoding RNAs
- 10 ncRNAs in clinical practice
- References
- Further reading
- Chapter Eleven Viral miRNAs role as diagnostic, prognostic biomarkers for cancer and infectious diseases
- Abstract
- 1 Introduction
- 2 Prospects of viral microRNA as potential biomarkers in cancer
- 3 Antiapoptotic viral miRNAs
- 4 Viral miRNAs in tumor progression
- 5 Prospects of viral microRNAs as potential biomarkers in infectious diseases
- 6 Viral miRNA detection platforms
- 7 Advantages of viral miRNAs as biomarkers
- 8 Future challenges
- References
- Chapter Twelve Pharmacogenomics and oncology: A therapeutic approach for cancer treatment
- Abstract
- Conflict of interest
- 1 Introduction
- 2 Targeting biomarkers in cancer therapy
- 3 Conclusion
- References
- Chapter Thirteen Obesity: Emerging risk factor for cancer beyond metabolic syndrome
- Abstract
- 1 Introduction
- 2 Epidemiologic evidences supporting the link between obesity and cancer
- 3 Effect of weight gain and weight loss paradigm in regulating cancer risk
- 4 Pathophysiology of obesity mediated cancer
- 5 Prevention and treatment
- 6 Conclusion
- References
- Chapter Fourteen Homologous repair deficiency and PARP inhibitors in cancer management
- Abstract
- Acknowledgment
- 1 DNA damage and repair
- 2 Homologous recombination deficiency
- 3 Biomarkers to evaluate HRD status
- 4 PARP inhibitors
- 5 Future perspectives
- References
- Chapter Fifteen Molecular prospects of transcription activator-like effector nucleases (TALENs) in cancer management: Challenges and adaptations
- Abstract
- 1 Introduction
- 2 Emergence and principles of technique
- 3 TALENs in cancer management
- 4 Executing challenges, limitations, and adaptations in TALENs
- 5 Concluding remarks
- 6 Future prospects
- References
- Chapter Sixteen Immunopeptidomic approaches for management of cancer
- Abstract
- 1 Introduction to immunopeptidomics
- 2 Identification of peptide-HLA antigen
- 3 Translating immunopeptidomics to immunotherapy
- References
- Chapter Seventeen Regulation of tumor microenvironment by nutrient trafficking
- Abstract
- 1 Introduction
- 2 TME and changes in tumor cells metabolism
- 3 Nutrients and cancer cell metabolism
- 4 Strategies adopted by cancer cells to alter the tumor microenvironment via metabolic reprogramming
- 5 Cancer metabolism based therapies
- 6 Conclusion and future directions
- References
- Chapter Eighteen Environmental factors influencing epigenetic changes initiating neoplastic changes
- Abstract
- 1 Introduction
- 2 Epigenetic mechanisms influencing gene expression
- 3 Environmental influences on epigenetic changes
- 4 Chemically influenced epigenetic changes
- 5 Trichloroacetic acid (TCA), trichloroethylene (TCE), and dichloroacetic acid (DCA)
- 6 Reproductive toxicants and chemicals disrupting endocrine mechanisms
- 7 Epigenetic drugs
- 8 DNMT inhibitors
- 9 HDAC inhibitors
- 10 Innovative epigenetic targets as research hotspots
- 11 Combination of epigenetic drugs with other treatment options for cancer
- 12 Conclusion and future perspectives
- References
- Chapter Nineteen Somatic mutation: Pharmacogenomics in oncology care
- Abstract
- 1 Introduction
- 2 Cancer pharmacogenomics
- 3 Somatic mutation
- 4 Biomarkers
- 5 Future direction
- 6 Conclusion
- References
- Chapter Twenty Precision medicine: Dose for anticancer therapy
- Abstract
- 1 Introduction
- 2 Pathophysiology of cancer
- 3 Pharmacogenetics in cancer
- 4 Types of enzymes and transporters responsible for pharmacokinetics of anticancer drugs
- 5 Future perspectives
- 6 Concluding remarks
- References
- Index
- Edition: 1
- Published: November 16, 2023
- No. of pages (Paperback): 398
- No. of pages (eBook): 400
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323951166
- eBook ISBN: 9780323951173
RS
Ranbir Chander Sobti
Dr. Ranbir Chander (RC) Sobti is Emeritus Professor at Punjab University, Chandigarh, and Honorary Scientist at the Indian National Science Academy. He started his career as a cytogeneticist and progressed to molecular biology and disease processes of cancer, COPD, AIDS, metabolic syndrome, and kidney diseases. He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases Royal Society of biology and international Association of Cancer Research. Dr. Sobti has participated in several book projects, including Elsevier’s Advances in Animal Experimentation and Modeling; Biomarkers in Cancer Detection and Monitoring of Therapeutics; Molecular Medicine and Biomedical Research in the Era of Precision Medicine; One Planet, One Health, One Future; Probiotics; and Public and Environmental Health.
Affiliations and expertise
Department of Biotechnology, Panjab University, Chandigarh, IndiaAK
Awtar Krishan
Dr. Awtar Krishan PhD is a world-renowned scientist. He obtained his PhD from Panjab University (1962) and the Univ. of Western Ontario, Canada (1963) in Cytogenetics and Anatomy. From 1965 to 1977, he was at the Sidney Farber Cancer Institute, Harvard Medical School as Head of the Tissue Ultrastructure and Experimental Pathology Labs. He has developed flow cytometric techniques for rapid analysis of DNA content by hypotonic propidium iodide, monitoring of drug retention and resistance, and more recently for monitoring hormone receptor expression in archival tumors. He is currently Director, Analytical Cytometry Laboratory, at University of Miami.
Affiliations and expertise
Professor, Sylvester Comprehensive Cancer Center, University of Miami Health System, USAAS
Aastha Sobti
Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology. Aastha Sobti has written two books with Elsevier: "Biomarkers in Cancer Detection and Monitoring of Therapeutics" (2023) and Molecular Medicine and Biomedical Research in the Era of Precision Medicine (2025).
Affiliations and expertise
Doctoral student, Department of Immunotechnology, Lund University, Lund, SwedenRead Biomarkers in Cancer Detection and Monitoring of Therapeutics on ScienceDirect